A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

NCT07161414 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: IV Rilvegostomig
DRUG: Recombinant Human Hyaluronidase (rHu)
DRUG: SC Rilvegostomig
DRUG: SC rilvegostomig + rHu

Sponsor

AstraZeneca

Collaborators

[object Object]